Extra spacing can boost children’s reading speed: New study finds significant benefits for both dyslexic and non-dyslexic children
A new study has found that a child’s reading speed can be improved by simply increasing the space between letters within a piece of text. The research, led by Dr Steven Stagg of Anglia Ruskin University (ARU), examined the benefits of letter spacing and coloured overlays amongst a group of dyslexic and non-dyslexic children. It […]
PSMA PET Plus MRI Better Detects Clinically Significant Prostate Cancers
MRI combined with prostate-specific membrane antigen (PSMA) PET improved the detection of clinically significant prostate cancer compared with MRI alone, and can potentially allow for a reduction in the number of biopsies needed for diagnosis, according to results from the PRIMARY trial. The combined approach demonstrated an increase in negative predictive value for detecting prostate […]
Can Working Out Slow Prostate Cancer Progression?
Rigorous exercise not only boosted cardiorespiratory fitness, but also improved indicators of prostate cancer biochemical progression in patients undergoing active surveillance, according to results of a randomized trial. Patients participating in a 12-week high-intensity interval training (HIIT) regimen saw an increase in peak oxygen consumption (VO2) — the study’s primary outcome — of 0.9 mL/kg/min, […]
Chemo Triplet May Boost Survival in Rare Soft-Tissue Sarcoma
Adding temozolomide to a combination of vincristine and irinotecan (VIT) improved tumor response and survival in patients with relapsed or refractory rhabdomyosarcoma in a European phase II trial. In the trial of over 100 patients, the group who received temozolomide had a numerically improved objective response rate (ORR) after two cycles of treatment versus the […]
PD-1 Inhibitor Boosts Survival in Treated Esophageal Cancer
Overall survival (OS) in previously treated esophageal cancer improved significantly with the anti-PD-1 drug tislelizumab compared to chemotherapy, a phase III, randomized trial showed. Patients randomized to tislelizumab had a median OS of 8.6 months as compared with 6.3 months for patients who received chemotherapy alone. A prespecified subgroup analysis of patients from Europe and […]